InvestorsHub Logo
Followers 8
Posts 126
Boards Moderated 0
Alias Born 11/10/2022

Re: valiano post# 7650

Monday, 06/10/2024 1:27:57 PM

Monday, June 10, 2024 1:27:57 PM

Post# of 7805
the 1.75% March 2027 Convertible notes will be refinanced without a problem once they turn profitable and continue to grow revenue.

Institutions need to feel comfortable that no further dilutive raises are coming at current debt levels. If Revance can hit that $80 to $85M revenue target by Q4 and finish the year with over $165M in cash with a cash burn in the $25M range by Q4, and Daxi sales showing solid year/year growth and market share gains, gains in therapeutic and China sales starting to kick in by 2025, then this stock should trade at 4x 2024 sales = $1.1B market cap soon after the Q4 2024 Earnings call in February = $10.50/share.

Current share price has priced in at least a 20 to 40% dilutive raise in 2025 IMO, and I don't see that being the case. I see this as a binary outcome with an action date Feb 2025 or 8 months out.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RVNC News